Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm

Executive Summary

Schwarz is expected to launch generic omeprazole by the end of year after FDA approval Nov. 1

Related Content

Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005
Neurontin, Rebetol Generics Could Be Affected By “Shared Exclusivity” Ruling
Schwarz Omeprazole Strategy, Part 2: DTC Ads, No Further Price Cuts
Generic Firms Warned Of First-To-File Risk: Willful Infringement Cases Rising
AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec 
Schwarz Omeprazole On Track For $1 Bil.; Transforming Event For Company?
Schwarz Omeprazole Launch Is Limited By Manufacturing Capacity
Singulair Allergy Approval Will Drive Sales Despite OTC Claritin, Merck Says
Andrx Altocor Sales Force Expands 50%; Generic Prilosec Charge Is $41 Mil.
Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts